194 related articles for article (PubMed ID: 3881480)
1. Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall.
Larsson A; Astedt B
J Clin Pathol; 1985 Feb; 38(2):140-5. PubMed ID: 3881480
[TBL] [Abstract][Full Text] [Related]
2. Immunological comparison between human and rat plasminogen activators in blood and the vessel wall.
Kjaeldgaard A; Larsson B; Astedt B
J Clin Pathol; 1984 Oct; 37(10):1153-6. PubMed ID: 6541663
[TBL] [Abstract][Full Text] [Related]
3. Human endothelial cells contain one type of plasminogen activator.
Kristensen P; Larsson LI; Nielsen LS; Grøndahl-Hansen J; Andreasen PA; Danø K
FEBS Lett; 1984 Mar; 168(1):33-7. PubMed ID: 6538515
[TBL] [Abstract][Full Text] [Related]
4. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
5. Immunological characterization of plasminogen activators in human mixed saliva.
Kjaeldgaard A; Kjaeldgaard M
Acta Physiol Scand; 1986 Mar; 126(3):443-7. PubMed ID: 3515850
[TBL] [Abstract][Full Text] [Related]
6. Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Gershtein ES; Medvedeva SV; Babkina IV; Kushlinskii NE; Trapeznikov NN
Bull Exp Biol Med; 2001 Jul; 132(1):670-4. PubMed ID: 11687850
[TBL] [Abstract][Full Text] [Related]
7. Changes in vessel wall plasminogen activator activity and smooth muscle cell proliferation and activation after arterial injury.
More RS; Underwood MJ; Brack MJ; de Bono DP; Gershlick AH
Cardiovasc Res; 1995 Jan; 29(1):22-6. PubMed ID: 7895234
[TBL] [Abstract][Full Text] [Related]
8. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
9. Effect of IUD on urokinase-like immunoreactivity and plasminogen activators in human uterine fluid.
Casslén B; Thorell J; Astedt B
Contraception; 1981 Apr; 23(4):435-45. PubMed ID: 7023822
[TBL] [Abstract][Full Text] [Related]
10. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
11. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
Cassels R; Fears R; Smith RA
Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
[TBL] [Abstract][Full Text] [Related]
12. Differences in the reactivities of human urokinase and the porcine tissue plasminogen activator.
Thorsen S; Astrup T
Haemostasis; 1976; 5(5):295-305. PubMed ID: 14058
[TBL] [Abstract][Full Text] [Related]
13. Changes in pericardial morphology and fibrinolytic activity during cardiopulmonary bypass.
Nkere UU; Whawell SA; Thompson EM; Thompson JN; Taylor KM
J Thorac Cardiovasc Surg; 1993 Aug; 106(2):339-45. PubMed ID: 8341074
[TBL] [Abstract][Full Text] [Related]
14. Relations between activation and inhibition of fibrinolysis in the walls of human arteries and veins.
Hegt VN
Thromb Haemost; 1977 Aug; 38(2):407-19. PubMed ID: 579485
[TBL] [Abstract][Full Text] [Related]
15. Tissue plasminogen activator activity in prostatic cancer.
Köller A; Kirchheimer J; Pflüger H; Binder BR
Eur Urol; 1984; 10(6):389-94. PubMed ID: 6085049
[TBL] [Abstract][Full Text] [Related]
16. Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia.
Roes EM; Sweep CG; Thomas CM; Zusterzeel PL; Geurts-Moespot A; Peters WH; Steegers EA
Am J Obstet Gynecol; 2002 Oct; 187(4):1019-25. PubMed ID: 12388999
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
18. Immunological identification of plasminogen activators in normal and malignant tissues of the oral cavity in man.
Ljungnér H; Björlin G; Astedt B
Int J Oral Surg; 1984 Aug; 13(4):334-8. PubMed ID: 6434453
[TBL] [Abstract][Full Text] [Related]
19. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
[TBL] [Abstract][Full Text] [Related]
20. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
